A phase II trial NCT00684983 was conducted to investigate the hypothesis that adding cituxumumab, an inhibitor of the insulin growth factor-1 receptor (IGF-1R), to the regimen of lapatinib and capecitabine would lead to improved prognosis and overcome trastuzumab resistance in patients with HER2-positive advanced BC. This evidence concerns the gene ERBB2 and breast cancer.